UBS maintains Pfizer stock rating ahead of cancer drug trial results

UBS maintains Pfizer stock rating ahead of cancer drug trial results  Investing.com Canada

Summary aggregated from Investing.com Canada's public RSS feed. The full reporting belongs to Investing.com Canada — please read it on their site.